The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort

Roos J. Jutten; John E. Harrison; A. J. Brunner; R. Vreeswijk; R. A.J. van Deelen; Frank Jan de Jong; Esther M. Opmeer; Craig W. Ritchie; André Aleman; Philip Scheltens; Sietske A.M. Sikkes

doi:10.1002/trc2.12020

The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort

Roos J. Jutten^*, John E. Harrison, A. J. Brunner, R. Vreeswijk, R. A.J. van Deelen, Frank Jan de Jong, Esther M. Opmeer, Craig W. Ritchie, André Aleman, Philip Scheltens, Sietske A.M. Sikkes

^*Corresponding author for this work

Clinical Neuropsychology

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we developed the Cognitive-Functional Composite (CFC). We investigated the CFC's sensitivity to decline in comparison to traditional clinical endpoints. Methods: This longitudinal construct validation study included 148 participants with subjective cognitive decline, mild cognitive impairment, or mild dementia. The CFC and traditional tests were administered at baseline, 3, 6, and 12 months. Sensitivity to change was investigated using linear mixed models and r² effect sizes. Results: CFC scores declined over time (β = −.16, P <.001), with steepest decline observed in mild Alzheimer's dementia (β = −.25, P <.001). The CFC showed medium-to-large effect sizes at succeeding follow-up points (r²=.08-.42), exhibiting greater change than the Clinical Dementia Rating scale (r²=.02-.12). Moreover, change on the CFC was significantly associated with informant reports of cognitive decline (β =.38, P <.001). Discussion: By showing sensitivity to decline, the CFC could enhance the monitoring of disease progression in dementia research and clinical practice.

Original language	English
Article number	e12020
Pages (from-to)	1-11
Number of pages	11
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	6
Issue number	1
Early online date	17 Apr 2020
DOIs	https://doi.org/10.1002/trc2.12020
Publication status	Published - 2020

Funding

The authors would like to thank Philippe Lee Meeuw Kjoe, Mandy Ter Haar, Larissa Masselink, Judith Meurs, Mieke Geertsma, Nina Schimmel, Ilya de Groot, Judy van Hemmen, Kate Forsyth, Sarah Gregory, Neil Fullerton, Clare Dolan, and Matthew Hunter for their help with the data collection. Additionally, we would like to acknowledge Stichting Buytentwist for their support. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc Fonds. The present study is supported by a grant from Memorabel (grant no. 733050205), which is the research program of the Dutch Deltaplan for2 Dementia. R.J.J., A.B., R.V., R.A.J.D, F.J.J, C.W.R., E.O.M., and A.A. report no relevant disclosures. In the past 2 years, J.H. has received honoraria and paid consultancy from 23andMe, Abbvie, A2Q, AlzCure, Amgen, Anavex, Aptinyx, Astellas, AstraZeneca, Avraham, Axon, Axovant, Biogen, Boehringer Ingelheim, Bracket, Catenion, Cognition Therapeutics, CRF Health, Curasen, DeNDRoN, Enzymotec, Eisai, Eli Lilly, GfHEu, Heptares, Johnson & Johnson, Kaasa Health, Lysosome Therapeutics, Lundbeck, Merck, MyCognition, Mind Agilis, Neurocog, Neurim, Neuroscios, Neurotrack, Novartis, Nutricia, Pfizer, PriceSpective, Probiodrug, Regeneron, Rodin Therapeutics, Roche, Sanofi, Servier, Shire, Takeda, and vTv Therapeutics. P.S. has acquired grant support (for the institution) from GE Healthcare and Piramal. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Novartis, Probiodrug, Biogen, Roche, and EIP Pharma, LLC. S.A.M.S. is supported by grants from JPND and Zon‐MW, and has provided consultancy services in the past 2 years for Nutricia and Takeda. All funds were paid to her institution.

Funders	Funder number
Dutch Deltaplan for2 Dementia
Nutricia and Takeda
Stichting Buytentwist	733050205
EU Joint Programme – Neurodegenerative Disease Research

Keywords

Alzheimer's disease
cognition
dementia
instrumental activities of daily living
mild cognitive impairment
outcome measures

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/trc2.12020

Persistent URL (handle)

Persistent link

Cite this

Jutten, R. J., Harrison, J. E., Brunner, A. J., Vreeswijk, R., van Deelen, R. A. J., de Jong, F. J., Opmeer, E. M., Ritchie, C. W., Aleman, A., Scheltens, P., & Sikkes, S. A. M. (2020). The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 6(1), 1-11. Article e12020. https://doi.org/10.1002/trc2.12020

@article{f83cff373657487fafcc3403b8aaa7b4,

title = "The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort",

abstract = "Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we developed the Cognitive-Functional Composite (CFC). We investigated the CFC's sensitivity to decline in comparison to traditional clinical endpoints. Methods: This longitudinal construct validation study included 148 participants with subjective cognitive decline, mild cognitive impairment, or mild dementia. The CFC and traditional tests were administered at baseline, 3, 6, and 12 months. Sensitivity to change was investigated using linear mixed models and r2 effect sizes. Results: CFC scores declined over time (β = −.16, P <.001), with steepest decline observed in mild Alzheimer's dementia (β = −.25, P <.001). The CFC showed medium-to-large effect sizes at succeeding follow-up points (r2=.08-.42), exhibiting greater change than the Clinical Dementia Rating scale (r2=.02-.12). Moreover, change on the CFC was significantly associated with informant reports of cognitive decline (β =.38, P <.001). Discussion: By showing sensitivity to decline, the CFC could enhance the monitoring of disease progression in dementia research and clinical practice.",

keywords = "Alzheimer's disease, cognition, dementia, instrumental activities of daily living, mild cognitive impairment, outcome measures",

author = "Jutten, {Roos J.} and Harrison, {John E.} and Brunner, {A. J.} and R. Vreeswijk and {van Deelen}, {R. A.J.} and {de Jong}, {Frank Jan} and Opmeer, {Esther M.} and Ritchie, {Craig W.} and Andr{\'e} Aleman and Philip Scheltens and Sikkes, {Sietske A.M.}",

year = "2020",

doi = "10.1002/trc2.12020",

language = "English",

volume = "6",

pages = "1--11",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

Jutten, RJ, Harrison, JE, Brunner, AJ, Vreeswijk, R, van Deelen, RAJ, de Jong, FJ, Opmeer, EM, Ritchie, CW, Aleman, A, Scheltens, P & Sikkes, SAM 2020, 'The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 6, no. 1, e12020, pp. 1-11. https://doi.org/10.1002/trc2.12020

The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. / Jutten, Roos J.; Harrison, John E.; Brunner, A. J. et al.
In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 6, No. 1, e12020, 2020, p. 1-11.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - The Cognitive-Functional Composite is sensitive to clinical progression in early dementia

T2 - Longitudinal findings from the Catch-Cog study cohort

AU - Jutten, Roos J.

AU - Harrison, John E.

AU - Brunner, A. J.

AU - Vreeswijk, R.

AU - van Deelen, R. A.J.

AU - de Jong, Frank Jan

AU - Opmeer, Esther M.

AU - Ritchie, Craig W.

AU - Aleman, André

AU - Scheltens, Philip

AU - Sikkes, Sietske A.M.

PY - 2020

Y1 - 2020

N2 - Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we developed the Cognitive-Functional Composite (CFC). We investigated the CFC's sensitivity to decline in comparison to traditional clinical endpoints. Methods: This longitudinal construct validation study included 148 participants with subjective cognitive decline, mild cognitive impairment, or mild dementia. The CFC and traditional tests were administered at baseline, 3, 6, and 12 months. Sensitivity to change was investigated using linear mixed models and r2 effect sizes. Results: CFC scores declined over time (β = −.16, P <.001), with steepest decline observed in mild Alzheimer's dementia (β = −.25, P <.001). The CFC showed medium-to-large effect sizes at succeeding follow-up points (r2=.08-.42), exhibiting greater change than the Clinical Dementia Rating scale (r2=.02-.12). Moreover, change on the CFC was significantly associated with informant reports of cognitive decline (β =.38, P <.001). Discussion: By showing sensitivity to decline, the CFC could enhance the monitoring of disease progression in dementia research and clinical practice.

AB - Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we developed the Cognitive-Functional Composite (CFC). We investigated the CFC's sensitivity to decline in comparison to traditional clinical endpoints. Methods: This longitudinal construct validation study included 148 participants with subjective cognitive decline, mild cognitive impairment, or mild dementia. The CFC and traditional tests were administered at baseline, 3, 6, and 12 months. Sensitivity to change was investigated using linear mixed models and r2 effect sizes. Results: CFC scores declined over time (β = −.16, P <.001), with steepest decline observed in mild Alzheimer's dementia (β = −.25, P <.001). The CFC showed medium-to-large effect sizes at succeeding follow-up points (r2=.08-.42), exhibiting greater change than the Clinical Dementia Rating scale (r2=.02-.12). Moreover, change on the CFC was significantly associated with informant reports of cognitive decline (β =.38, P <.001). Discussion: By showing sensitivity to decline, the CFC could enhance the monitoring of disease progression in dementia research and clinical practice.

KW - Alzheimer's disease

KW - cognition

KW - dementia

KW - instrumental activities of daily living

KW - mild cognitive impairment

KW - outcome measures

UR - http://www.scopus.com/inward/record.url?scp=85091027265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091027265&partnerID=8YFLogxK

U2 - 10.1002/trc2.12020

DO - 10.1002/trc2.12020

M3 - Article

AN - SCOPUS:85091027265

SN - 2352-8737

VL - 6

SP - 1

EP - 11

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

M1 - e12020

ER -

Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ et al. The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2020;6(1):1-11. e12020. Epub 2020 Apr 17. doi: 10.1002/trc2.12020

The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort

Abstract

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this